A Comparison of Screening Tools for the Early Detection of Peripheral Neuropathy in Adults with and without Type 2 Diabetes
Table 1
NCS results.
(a) Sural nerve amplitude potentials and conduction velocities
N
Min
Max
Mean
Std. error
Std. dev.
SNAP-R (μV)
OOI
10
2
14.3
6.631
1.444
4.567
PD
13
2
24.7
7.691
1.674
6.037
T2D
11
2
25
9.875
2.133
7.076
SNAP-L (μV)
OOI
10
2.3
21.7
7.129
1.834
5.798
PD
13
3
21.7
7.277
1.186
4.277
T2D
11
3
21.7
10.572
2.064
6.847
SNCV-R (μV)
OOI
10
35.3
55.7
46.2
1.902
6.016
PD
13
30
57
48.2
1.871
6.747
T2D
11
35.3
57
45.5
1.816
6.022
SNCV-L (μV)
OOI
10
41.3
55
47.265
1.519
4.803
PD
13
43
55
49.637
1.072
3.865
T2D
11
37.3
57
46.876
1.946
6.455
(b) Sensitivity and specificity of screening tests and subcomponents
Prevalence
Sensitivity
Specificity
PPV
NPV
128 Hz tuning fork
52.90%
50.00%
75.00%
69.20%
57.10%
1 g monofilament
26.50%
66.70%
72.00%
46.20%
85.70%
10 g monofilament
55.90%
47.40%
73.30%
69.20%
52.40%
QOL-DN total
29.40%
60.00%
70.80%
46.20%
81.00%
QOL-DN symptoms
32.40%
36.40%
60.90%
30.80%
66.70%
QOL-DN large fiber
35.30%
58.30%
72.70%
53.80%
76.20%
QOL-DN small fiber
97.10%
39.40%
100.00%
100.00%
4.80%
QOL-DN ADLS
76.50%
42.30%
75.00%
84.60%
28.60%
QOL-DN autonomic
61.80%
42.90%
69.20%
69.20%
42.90%
Normoglycemic, PD, and T2D. PPV = positive predictive value; NPV = negative predictive value; based off R/L SNAP values. Prevalence indicates presence of findings for indications of neuropathy.
